钠-葡萄糖协同转运蛋白2抑制剂治疗青年发病的成年型糖尿病（MODY）的疗效与安全性：一例病例报告及文献综述
Efficacy and safety of SGLT2 inhibitors in the treatment of maturity-onset diabetes of the young (MODY): a case report and literature review.
作者信息
Bombonato Michelle, Beccuti Guglielmo, Benso Andrea, Giannone Beatrice, Bertaina Silvana, Broglio Fabio, Bioletto Fabio
机构信息
Division of Endocrinology, Diabetes and Metabolism, Department of Medical Sciences, University of Turin, Corso Dogliotti 14, 10126, Turin, Italy.
出版信息
Hormones (Athens). 2025 Feb 4. doi: 10.1007/s42000-025-00632-8.
BACKGROUND
Sulfonylureas constitute the standard therapy for patients with HNF1A-MODY (maturity-onset diabetes of the young) but are characterized by an increased risk of hypoglycemia. While SGLT2 inhibitors (SGLT2i) may potentially represent a useful therapeutic option, data from the literature are scant.
CASE PRESENTATION
We report the case of a young woman affected by HNF1A-MODY who was successfully and safely treated with an SGLT2i in addition to sulfonylurea. After SGLT2i initiation, an improvement in the patient's glycemic control was observed and was maintained over time. No adverse effects were noted and, in particular, no increase in ketonemia or ketonuria occurred.
CONCLUSIONS
The use of SGLT2i under controlled circumstances may represent a useful therapeutic option in patients with HNF1A-MODY.
背景
磺脲类药物是年轻的成人发病型糖尿病（HNF1A-MODY）患者的标准治疗药物，但具有低血糖风险增加的特点。虽然钠-葡萄糖协同转运蛋白2抑制剂（SGLT2i）可能是一种有用的治疗选择，但文献数据较少。
病例报告
我们报告了一例患有HNF1A-MODY的年轻女性病例，该患者除接受磺脲类药物治疗外，还成功且安全地接受了SGLT2i治疗。开始使用SGLT2i后，观察到患者血糖控制得到改善，并持续保持。未观察到不良反应，特别是酮血症或酮尿症未增加。
结论
在可控情况下使用SGLT2i可能是HNF1A-MODY患者的一种有用治疗选择。
Zotero 插件